Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Timothy grass pollen allergen Phl p 1 is a 27–35 kDa glycoprotein belonging to the beta-expansin family, specifically categorized as a Group 1 grass pollen allergen [UniProt P43213, Thermo Fisher Scientific]. In its native plant environment, it acts as a non-enzymatic cell wall-loosening agent that facilitates fertilization by allowing the pollen tube to penetrate the maternal tissues of the stigma and style [PubMed 10424508, Wikipedia]. In humans, Phl p 1 is the primary initiator of grass pollen allergy, with more than 90% of grass-pollen-allergic individuals exhibiting specific IgE reactivity to this protein [PMC4106562, PMC4607271]. Upon inhalation, Phl p 1 cross-links IgE on the surface of mast cells and basophils, leading to the release of inflammatory mediators and the clinical symptoms of allergic rhinitis and asthma [PubMed 19694723]. This allergen is a critical target for allergen-specific immunotherapy (AIT), where it is administered in standardized extracts or recombinant forms to induce long-term immunological tolerance by shifting the immune response from a Th2 to a Th1 profile [PMC3073371, PMC3166668].
Allergen-specific immunotherapy (AIT) utilizing Phl p 1 induces peripheral immune tolerance by promoting a shift from a Th2-mediated allergic response to a Th1-mediated response. This process involves the induction of regulatory T cells (Tregs) that secrete suppressive cytokines like IL-10 and TGF-beta, and the stimulation of B cells to produce allergen-specific 'blocking antibodies' (IgG4 and IgA). These antibodies compete with IgE for binding to Phl p 1, thereby preventing the degranulation of mast cells and basophils upon subsequent allergen exposure [PMC3073371, PMC3166668, ResearchGate 2025].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Timothy grass pollen allergen Phl p 1 (Phl p 1).